| Literature DB >> 30640465 |
James S Scott, Andrew Bailey, David Buttar, Rodrigo J Carbajo, Jon Curwen, Paul R J Davey, Robert D M Davies, Sébastien L Degorce, Craig Donald, Eric Gangl1, Ryan Greenwood, Sam D Groombridge, Tony Johnson, Scott Lamont, Mandy Lawson, Andrew Lister, Christopher J Morrow, Thomas A Moss, Jennifer H Pink, Radoslaw Polanski.
Abstract
Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray crystal structures and NMR conformational work, varied the alkyl side chain and pendant aryl group and resulted in compounds with low turnover in human hepatocytes and enhanced chemical stability. Compound 9 was profiled as a representative of the series in terms of pharmacology and demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.Entities:
Year: 2019 PMID: 30640465 DOI: 10.1021/acs.jmedchem.8b01837
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446